Press Release
18 June 2024 08:50:00 CEST

Neola Medical's CEO Announces Key Achievements in the Summer 2024 Investor Letter

Neola Medical has reached several critical milestones aligned with its business strategy, aimed at market approval by the FDA. A Human Factors Validation Study of the company's medical device for lung monitoring, Neola®, was successfully concluded with neonatal nurses in the USA, and will lay a foundation for the upcoming market grant application to FDA. Additionally, Neola® obtained a CB certificate according to high International standards, meeting partial regulatory requirements for market approval in the USA.

"These achievements lay a strong foundation for our upcoming FDA application for market approval in the USA. We now advance to the clinical validation phase and intensify planning for the clinical study in the USA on preterm born infants.", says CEO Hanna Sjöström.

Read more about the latest news in the investor letter summer 2024, attached to this press release and available on the company's website www.neolamedical.se

For further information, contact:
Hanna Sjöström, CEO
e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical
Neola Medical AB (publ) develops revolutionizing medical technology device for non-invasive continuous lung monitoring and real-time alerts of life-threatening lung complications of preterm born infants. Immediate detection of complications provides the possibility of early treatment, improved health care and healthier lives for preterm born infants. The patented cutting-edge technology is developed at Lund University in Sweden and based on a spectroscopic method that measures lung volume changes and oxygen gas concentration. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

Attachments
Neola Medical's CEO Announces Key Achievements in the Summer 2024 Investor Letter
Neola Medical Investor Letter Summer 2024